AriBio Co., Ltd. has partnered with Kentucky Clinical Trial Laboratory (KCTL) to enhance Alzheimer’s disease testing. This collaboration will improve access to accurate and efficient testing of cerebral spinal fluid (CSF) using the Lumipulse® system from FujireBio.
Samples from AriBio’s Phase 3 POLARIS-AD trial, investigating the efficacy of AR1001 in early Alzheimer’s patients, will be tested for the Aβ42/40 ratio using an FDA-approved Lumipulse® system assay. The trial also assesses other endpoints, including CDR-SB, ADAS-Cog 13, I-IADL, GDS, and MMSE, as well as changes in CSF and plasma biomarkers.
This partnership will support AriBio’s development of therapeutics for neurodegenerative diseases. The advanced diagnostics provided by KCTL enable a better understanding of patient progression and the impact of treatment on biomarkers.
KCTL is a CLIA-Certified laboratory specializing in clinical trial services for IVD and pharmaceutical manufacturers. Its expertise in cardiovascular, neurological, and cancer biomarker studies will contribute to advancements in Alzheimer’s disease research.
AriBio continues to explore collaborations to accelerate the development of innovative treatments and enhance understanding of neurodegenerative diseases.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
